MCUJF - Hospital Cath Labs are switching from more expensive options such as REOPRO and INTEGRILIN to AGGRASTAT. Most of these conversions are happening without the need for an expensive sales/commercial team.
The cost savings to the institutions are significant. Anywhere from 50% to 70% cost savings opportunity. When you are factoring in a $600 to $900 saving per patient undergoing PCI, there are hospitals and health systems that could save 10's of thousands to 100's of thousands of dollars on the hospital level...Millions of dollars on the large system level.
High dose AGGRASTAT may offer additional safety benefits over REOPRO and INTEGRILIN in patients undergoing PCI, as well as equivalent efficacy data...No large trials to directly compare these agents, but enough data in the literature to formulate a solid hypothesis...
MERCK screwed up years ago. They didn't listen to the key clinical trialists....
Which means...Great for anyone invested in Medicure at this point...
Also, with MDCO's anti-platelet option coming out at a higher price point, you may see an up-tic in GP IIb/IIIa inhibition utilization.
News 
Market Data 
Discover 
